BACKGROUND: micro-Opiate receptor agonism has been associated with weight gain, whereas micro-antagonists have been associated with weight neutrality, or even weight loss. AIM: This study examined the course of weight changes in opiate-dependent patients over the first 6 months of treatment in methadone (agonist) versus naltrexone (antagonist) maintenance. DESIGN: A retrospective chart review was conducted on 36 opiate-dependent patients maintained on methadone (n=16) or naltrexone (n=20). OUTCOME MEASURES AND ANALYSES: The primary outcome measure was change in body weight from baseline to 3 months and 6 months into treatment. Analysis of variance was used to compare mean weights between the methadone- and naltrexone-maintained patients. Secondarily, mean percent weight changes from baseline to 3 months and from baseline to 6 months into treatment were compared using Student's t-test. RESULTS: There was no difference between weight at baseline, 3 months, or 6 months into treatment between the two treatment groups. Furthermore, there was also no difference between the two groups regarding percent weight change from baseline to 3 months or baseline to 6 months. At 3 months, n=16 methadone patients had a mean weight increase of 1.86 percent (standard deviation [SD] = 7.22 percent) when compared with n=20 Behavioral Naltrexone Therapy (BNT) patients with an increase of 4.63 percent (SD = 6.49 percent). At 6 months, n=16 methadone patients had a mean weight increase relative to baseline of 3.67 percent (SD = 9.52percent) when compared with n=20 BNT patients, who demonstrated a mean increase of 6.69 percent (SD = 7.56 percent). No association was found between baseline weight, defined as "low" or "high" relative to group medians, and percent gain within and between treatment groups. CONCLUSIONS: This study did not detect a statistically different course of weight gain between methadone and naltrexone maintenance treatment for opiate-dependent patients.
BACKGROUND: micro-Opiate receptor agonism has been associated with weight gain, whereas micro-antagonists have been associated with weight neutrality, or even weight loss. AIM: This study examined the course of weight changes in opiate-dependent patients over the first 6 months of treatment in methadone (agonist) versus naltrexone (antagonist) maintenance. DESIGN: A retrospective chart review was conducted on 36 opiate-dependent patients maintained on methadone (n=16) or naltrexone (n=20). OUTCOME MEASURES AND ANALYSES: The primary outcome measure was change in body weight from baseline to 3 months and 6 months into treatment. Analysis of variance was used to compare mean weights between the methadone- and naltrexone-maintained patients. Secondarily, mean percent weight changes from baseline to 3 months and from baseline to 6 months into treatment were compared using Student's t-test. RESULTS: There was no difference between weight at baseline, 3 months, or 6 months into treatment between the two treatment groups. Furthermore, there was also no difference between the two groups regarding percent weight change from baseline to 3 months or baseline to 6 months. At 3 months, n=16 methadonepatients had a mean weight increase of 1.86 percent (standard deviation [SD] = 7.22 percent) when compared with n=20 Behavioral Naltrexone Therapy (BNT) patients with an increase of 4.63 percent (SD = 6.49 percent). At 6 months, n=16 methadonepatients had a mean weight increase relative to baseline of 3.67 percent (SD = 9.52percent) when compared with n=20 BNT patients, who demonstrated a mean increase of 6.69 percent (SD = 7.56 percent). No association was found between baseline weight, defined as "low" or "high" relative to group medians, and percent gain within and between treatment groups. CONCLUSIONS: This study did not detect a statistically different course of weight gain between methadone and naltrexone maintenance treatment for opiate-dependent patients.
Authors: C Colantuoni; J Schwenker; J McCarthy; P Rada; B Ladenheim; J L Cadet; G J Schwartz; T H Moran; B G Hoebel Journal: Neuroreport Date: 2001-11-16 Impact factor: 1.837
Authors: Anna Bogucka-Bonikowska; Helena Baran-Furga; Karina Chmielewska; Boguslaw Habrat; Anna Scinska; Andrzej Kukwa; Eliza Koros; Wojciech Kostowski; Elzbieta Polanowska; Przemyslaw Bienkowski Journal: Drug Alcohol Depend Date: 2002-09-01 Impact factor: 4.492
Authors: Jami L Rothenberg; Maria A Sullivan; Sarah H Church; Angela Seracini; Eric Collins; Herbert D Kleber; Edward V Nunes Journal: J Subst Abuse Treat Date: 2002-12
Authors: Traci A Czyzyk; Ruben Nogueiras; John F Lockwood; Jamie H McKinzie; Tamer Coskun; John E Pintar; Craig Hammond; Matthias H Tschöp; Michael A Statnick Journal: FASEB J Date: 2009-11-16 Impact factor: 5.191
Authors: Igor Elman; Margaret Howard; Jacob T Borodovsky; David Mysels; David Rott; David Borsook; Mark Albanese Journal: Sci Rep Date: 2020-03-27 Impact factor: 4.379